Translational Takeaways: May 31, 2026

This week’s dermatology literature reflects a field in active transition — not just in the addition of new agents, but in the reshaping of what optimal treatment looks like across multiple indications. Two long-term efficacy datasets in atopic dermatitis (AD) arrived simultaneously, and together they underscore a theme that deserves emphasis: in AD, time on therapy is not neutral. Response deepens. The question increasingly is not whether to treat, but how aggressively and for how long. In psoriatic arthritis, the first direct head-to-head comparison between IL-17 and IL-23 inhibition provides the kind of evidence that network meta-analyses never fully deliver. And in acne, an OTC switch that seems administrative on the surface has real implications for how dermatologists position themselves in mild to moderate disease management.

Atopic Dermatitis: Zumilokibart and the Case for an Injection-Minimizing Biologic

Apogee Therapeutics’ zumilokibart, an extended half-life anti-IL-13 monoclonal antibody, delivered comprehensively across all endpoints in the phase 2 APEX part B dose-ranging trial — and the pharmacokinetic design is what makes this worth watching beyond the efficacy numbers alone.¹

• 65.9%EASI-75 at week 16 (mid-dose) vs 23.4% placebo
• 46.0%IGA 0/1 at week 16 vs 10.9% placebo
• 20.6%EASI-90 + I-NRS 0/1 composite vs 4.5% placebo — not previously reported with any biologic
• 4 vs 9 Injection days required at induction vs current standard of care

Part A maintenance data are the critical complement to these induction numbers. Efficacy was not simply maintained with every-3- or every-6-month dosing through 52 weeks — in some measures, it continued to improve. If phase 3 confirms this profile, zumilokibart would offer a dosing schedule meaningfully less burdensome than anything currently approved in the class. The mid-dose was selected over the high dose based on comparable efficacy and a substantially lower conjunctivitis rate (10.6% vs 20.7%) — a clinically relevant distinction given how frequently that adverse event shapes biologic tolerability conversations in AD.

Translationally:The AD biologic field is converging on a question that goes beyond efficacy at week 16: which agents offer the best sustained disease control with the lowest treatment burden over time? Zumilokibart’s phase 3 program will be one of the more closely watched readouts in the space.

MORE DRUGS TO WATCH

Atopic Dermatitis: Two Years of Abrocitinib — Response Continues to Build

JADE EXTEND (NCT03422822), now reporting through week 112 in JEADV, provides the longest-duration dataset yet for abrocitinib and tells a consistent story: continued therapy produces continued improvement. The pattern is not plateau and maintenance — it is deepening response.²

• 84% / 78%EASI-75 at week 112 for 200 mg / 100 mg
• ~80%Patients achieving mild phenotype (EASI ≤7) by week 112, up from ~60% at week 12
• 37% / 30%EASI-90 + PP-NRS 0/1 composite at week 112 — consistent with AHEAD MDA criteria
• 43% / 33%PP-NRS 0/1 (near-complete itch resolution) at week 112

The trajectory is the headline. Response rates climbed from week 12 through week 48, then stabilized rather than eroding through week 112. Few patients experienced worsening over time. The composite endpoint aligning with minimal disease activity criteria reached 37% at 2 years — a threshold that would have seemed ambitious at trial initiation. The lack of dose switching in the protocol also means these data represent a clean read on sustained fixed-dose efficacy rather than a confounded picture.

Translationally: For clinicians making long-term management decisions about JAK inhibitors in AD, the JADE EXTEND data strengthen the argument for sustained therapy in responders. Two years in, the benefit-to-risk calculus has not shifted unfavorably.

MORE ON AD

Psoriatic Arthritis: First IL-17 vs IL-23 Head-to-Head Data

The BE BOLD (NCT06624228) trial, now with full 16-week data from EULAR 2026, closes a longstanding evidence gap in psoriatic arthritis: how do IL-17 and IL-23 inhibition compare directly? The answer, at least at week 16, favors bimekizumab on the primary joint endpoint.³

• 49.1% vs 38.4% ACR50 at week 16, bimekizumab vs risankizumab (p=0.0078)
• 19.9% vs 7.2% ACR50 at week 4 — earlier joint response with bimekizumab
• 33.5% vs 24.4% Simultaneous ACR50 + PASI 100 at week 16
• 65.3% vs 54.7% DAPSA low disease activity or remission at week 16

The nuance requires acknowledgment. The first-ranked secondary endpoint — minimal disease activity at week 16 (43.0% vs 39.9%) — did not reach statistical significance, which stopped the hierarchical testing sequence. All downstream secondary outcomes are therefore descriptive only. Candida infections were more frequent with bimekizumab, in keeping with dual IL-17A/F inhibition; all were mild to moderate with no discontinuations. The safety profiles were otherwise broadly comparable.

UCB’s characterization of this as the first biologic to demonstrate statistically significant ACR50 superiority over another biologic in a head-to-head PsA trial is technically accurate and clinically meaningful — prior head-to-head trials in PsA have compared against TNF inhibitors, not IL-23 inhibitors.

Translationally: For clinicians managing patients with both cutaneous psoriasis and active joint disease, BE BOLD provides direct comparative evidence rather than extrapolation. The data support bimekizumab as a strong option when early and robust joint response is a priority, with the understanding that the MDA signal was not statistically definitive at week 16.

MORE ON PSORIATIC CONDITIONS

Acne: Epiduo’s OTC Switch and What It Actually Changes

The FDA’s approval of adapalene 0.1%/BPO 2.5% for OTC use in patients 12 and older is less a clinical development than a practice context shift. The product is unchanged; what has changed is who controls access to it.⁴

• 70.3%Inflammatory lesion reduction at week 12 in supporting phase 3 program
• ~65%Total lesion reduction maintained through 12 months in long-term study
• Summer 2026 Projected retail availability at major US chains

The clinical case for this combination — targeting comedogenesis, inflammatory lesions, and C. acnes simultaneously — is established and guideline-supported. OTC availability expands access for mild to moderate acne patients who never seek clinical evaluation, which is a real public health benefit. The practical consequence for dermatology practices is more nuanced.

Patients with adequate OTC access and mild comedonal or inflammatory acne will increasingly self-manage. The patients presenting to dermatology will skew toward higher severity, scarring, nodulocystic disease, significant post-inflammatory dyspigmentation, or those who have failed OTC therapy. This is not a new dynamic — OTC differin (adapalene 0.1%) created a similar shift — but it warrants updating the implicit referral framework.

Counseling implications remain: retinoid/BPO combinations require consistent daily application, may produce early irritation and dryness, and should be paired with appropriate moisturization and photoprotection. Patients who show up having already started Epiduo OTC and are frustrated by week 2 irritation are a predictable new consultation pattern.

Translationally: Epiduo’s OTC switch does not reduce demand for dermatologic acne care; it filters the presenting population toward complexity. The clinical benchmark for dermatologist-directed acne therapy should be positioned accordingly.

MORE ON ACNE

Rare Vascular Conditions: Topical Rapamycin Approaches NDA Filing

Palvella Therapeutics presented expanded datasets from the SELVA phase 3 trial (microcystic LM) and TOIVA phase 2 trial (cutaneous VM) at the 2026 ISSVA World Congress. The SELVA results in pediatric patients are particularly striking.⁵

• 100% Patients aged 6–11 rated ‘much’ or ‘very much’ improved on mLM-IGA at week 24 (n=13)
• 87% With moderate/worse leaking or bleeding — much/very much improved at week 24 (n=23)
• 84% Reported extreme, very high, or high treatment satisfaction (TSQM-9)
• -1.50 / -1.43 Mean cVM-MCSS Height / Appearance reductions at week 24 (TOIVA, p<0.001)

Both studies were single-arm and baseline-controlled — a design limitation inherent to rare disease trials with small populations and no existing standard of care. The disease stability during the pre-treatment run-in period (mean mLM-MCSS change of -0.1 over 8 weeks, followed by -3.4 over 24 weeks of active treatment) provides reasonable evidence against spontaneous improvement accounting for the results. The FDA has granted Breakthrough Therapy, Orphan Drug, and Fast Track designations for the microcystic LM indication. An NDA filing is planned for the second half of 2026.

These are rare conditions, but dermatologists in academic and tertiary settings manage vascular anomaly referrals regularly. The absence of approved pharmacotherapy has historically confined management to procedural options: sclerotherapy, laser, surgery, and compression. A topical mTOR inhibitor with this response profile, if approved, would represent a meaningful option for a patient population that currently has none.

Translationally: Clinicians managing pediatric vascular anomaly referrals should be aware that the regulatory pathway for Qtorin rapamycin is advancing rapidly. If approved in 2027 as projected, it would become the first pharmacologic option in either indication.

MORE IN PEDIATRICS

Atopic Dermatitis — Safety: Upadacitinib Lab Profile Through 140 Weeks

The 140-week laboratory safety analysis from Measure Up 1 and 2, presented at the Society for Investigative Dermatology Annual Meeting, extends the safety dataset for upadacitinib in AD to nearly 3 years and finds no meaningful drift in laboratory parameters over time.⁶

• <2% Lab-related treatment discontinuations through week 140
• 0.6–1.3% Grade 3+ ALT elevations; 1.1–2.1% AST; most transient
• 8.6–12.5% Grade 3+ CPK elevations — typically mild, exercise-related, self-resolving
• 1.27–1.79 Weight gain events per 100 patient-years (dose-dependent)

The early CPK spike observed in the 30 mg group at week 4 (mean 414.5 U/L) normalized thereafter and was attributed to physical exertion rather than myopathy. Grade 4 CPK events remained under 6% and serious CPK events occurred at fewer than 0.1 events per 100 patient-years. Lipid and liver enzyme values remained largely within normal limits throughout, with any changes that did emerge generally resolving on continued therapy without dose modification.

The practical implication for prescribers is that routine monitoring per JAK inhibitor labeling remains standard of care, but the data provide reassurance that the monitoring yield is low in otherwise-stable patients. Lab abnormalities requiring discontinuation represent a rare event across a nearly 3-year observation window.

Translationally:These data support long-term prescribing confidence in appropriate patients and give dermatologists a specific, trial-derived dataset to reference when patients ask what to expect from their labs over time on upadacitinib.

MORE CONFERENCE COVERAGE

Aesthetic Dermatology: Engineered Neuromodulator Shows Extended Duration in Glabellar Lines

Phase 2 data from the LANTIC program for corabotase, Ipsen’s engineered recombinant neuroinhibitor, demonstrated a clear efficacy and durability signal in glabellar lines that warrants attention in aesthetic practice.⁷

• 66.0% ≥2-grade improvement at week 4 vs 0% placebo (p=0.0001)
• 60.8% None/mild severity at week 24 vs 36.7% abobotulinumtoxinA, 0.2% placebo
• 0.84 days Reported onset of action
• 82.8% Patient satisfaction at week 24

The engineering rationale is mechanistically coherent: by combining the type A catalytic domain with a type B binding domain, the molecule is designed to achieve higher receptor affinity, increased cellular uptake, and resistance to degradation — features that would plausibly support extended duration. Whether the design delivers meaningfully longer duration in randomized phase 3 trials, and whether that duration advantage comes without adverse trade-offs in ptosis, brow heaviness, diffusion, or immunogenicity, will be the key questions.

The press release did not disclose specific adverse event rates, immunogenicity data, or discontinuation rates — information that aesthetic practitioners will need before drawing conclusions about clinical positioning.

Translationally:Phase 3 is the critical test. The phase 2 profile is encouraging and the mechanism has biological plausibility, but the full safety picture is pending and will determine whether the duration advantage justifies any trade-offs.

References

1. Apogee Therapeutics announces positive 16-week part B induction dose optimization results from phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. News release. Apogee Therapeutics. Published May 27, 2026. Accessed May 29, 2026. https://investors.apogeetherapeutics.com/news-releases/news-release-details/apogee-therapeutics-announces-positive-16-week-part-b-induction
2. Gooderham MJ, Silverberg JI, De Bruin-Weller M, Kircik L, Thaçi D, Zhao Z, et al. Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years. J Eur Acad Dermatol Venereol. 2026;00:1–10. doi:10.1111/jdv.70439
3. BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD week 16 data. News release. UCB. Published May 19, 2026. Accessed May 29, 2026. https://www.ucb.com/newsroom/press-releases/article/bimzelxrbimekizumab-demonstrates-superior-efficacy-over-skyrizir-risankizumab-in-psoriatic-arthritis-be-bold-week-16-data
4. Galderma receives U.S. FDA approval for Differin Epiduo Acne Gel prescription-to-OTC switch. Galderma. May 22, 2026. Accessed May 29, 2026. https://www.galderma.com/news/galderma-receives-us-fda-approval-differin-epiduo-otc-switch
5. Palvella Therapeutics presents new SELVA and TOIVA data at the 2026 International Society for the Study of Vascular Anomalies World Congress supporting Qtorin rapamycin as a potential first-in-disease therapy for multiple serious, rare vascular malformations. News release. Palvella Therapeutics. May 20, 2026. Accessed May 29, 2026. https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-presents-new-selva-and-toiva-data-2026
6. Cotter D, Shahriari M, Dasilva D, et al. Long-term laboratory trends in patients with moderate‑to‑severe atopic dermatitis treated with upadacitinib: 140‑week results from measure up 1 and 2. Poster presented at the Society for Investigative Dermatology Annual Meeting, May 13–16, 2026, Chicago, Illinois.
7. Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction. Ispen. May 16, 2026. Accessed May 18, 2026. https://www.ipsen.com/press-release/ipsen-presents-first-in-class-late-breaking-phase-ii-corabotase-data-in-glabellar-lines-showing-sustained-duration-of-effect-reinforced-by-consistently-high-patient-satisfaction-3296217/